Mexiletine Shortens the QT Interval in Patients With Potassium Channel–Mediated Type 2 Long QT Syndrome
Authors:
- 1 May 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 12 (5) , e007280
Abstract
Background: Long QT syndrome is a potentially lethal yet highly treatable cardiac channelopathy. Although β-blocker therapy is standard for most patients, concomitant therapy with sodium channel blockers, like mexiletine, is often utilized for patients with sodium channel–mediated type 3 long QT syndrome (LQT3). The potential role of sodium channel blockers in patients with potassium channel–mediated long QT syndrome (ie, LQT1 and LQT2) has not been investigated in detail. Methods: We performed a retrospective chart review on 12 patients (5 females; median age at diagnosis 14.1 years (interquartile range [IQR], 7.7–23; range, 0–59, median heart rate–corrected QT interval [QTc] at diagnosis 557 ms (IQR, 529–605) with genetically established LQT2 (10) or a combination of LQT1/LQT2 (1) or LQT2/LQT3 (1), who received mexiletine. Data were collected on symptomatic status, treatments, and breakthrough cardiac events after diagnosis and initiation of treatment. Additionally, 12-lead ECGs were collected at diagnosis, before initiation of mexiletine and following mexiletine to evaluate the drug’s effect on QTc. Results: Before diagnosis, 6 patients were symptomatic and, before initiation of mexiletine, 4 patients experienced ≥1 breakthrough cardiac event on β-blocker. Median age at first mexiletine dose was 24.3 years (IQR, 14–32.4). After mexiletine, the median QTc decreased by 65±45 ms from 547 ms (IQR, 488–558) premexiletine to 470 ms (IQR, 409–529) postmexiletine ( P =0.0005) for all patients. In 8 patients (67%), the QTc decreased by ≥ 40 ms with a mean decrease in QTc of 91 ms ( P < 0.008). For the 11 patients maintained on mexiletine therapy, there have been no breakthrough cardiac events during follow-up. Conclusions: Although commonly prescribed in patients with LQT3, mexiletine also shortens the QTc significantly in two-thirds of a small subset of patients with potassium channel–mediated LQT2. In patients with LQT2, pharmacological targeting of the physiological late sodium current may provide added therapeutic efficacy to β-blocker therapy.Keywords
This publication has 35 references indexed in Scilit:
- Congenital Long QT 3 in the Pediatric PopulationThe American Journal of Cardiology, 2012
- Prevalence of the Congenital Long-QT SyndromeCirculation, 2009
- Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgeryHeart Rhythm, 2009
- Ion channel diseases in children: manifestations and managementCurrent Opinion in Cardiology, 2008
- Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT SyndromeCirculation, 2004
- Risk Stratification in the Long-QT SyndromeNew England Journal of Medicine, 2003
- Influence of the Genotype on the Clinical Course of the Long-QT SyndromeNew England Journal of Medicine, 1998
- Long QT Syndrome Patients With Mutations of the SCN5A and HERG Genes Have Differential Responses to Na + Channel Blockade and to Increases in Heart RateCirculation, 1995
- Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias: A two-year follow-upAmerican Heart Journal, 1989
- Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval, and sudden deathAmerican Heart Journal, 1957